{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:33:48Z","timestamp":1789475628085,"version":"build-2803163510"},"reference-count":37,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["71804025"],"award-info":[{"award-number":["71804025"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People\u2019s Republic of China","doi-asserted-by":"publisher","award":["WKZX2023CX210005"],"award-info":[{"award-number":["WKZX2023CX210005"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Gastric cancer is a leading cause of cancer-related mortality worldwide, and HER2-positive gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma constitutes an aggressive molecular subtype. The KEYNOTE-811 phase III trial demonstrated improved clinical outcomes with combination therapy of pembrolizumab, trastuzumab, and chemotherapy (PTC) compared to trastuzumab and chemotherapy alone (TC), but the economic value of this regimen remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the cost-effectiveness of the PTC regimen versus TC for unresectable metastatic HER2-positive G\/GEJ adenocarcinoma in the United States, stratified by PD-L1 combined positive score (CPS), and to evaluate the economic impact of real-world sequential treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A model-based pharmacoeconomic evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>A 10-year semi-Markov model was developed using data from the KEYNOTE-811 trial to estimate disease progression, costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Additionally, a 21-day cycle micro-simulation model was constructed to evaluate sequential treatment pathways involving first-line PTC or TC, followed by trastuzumab deruxtecan or ramucirumab plus paclitaxel, and third-line paclitaxel monotherapy or best supportive care. One-way and probabilistic sensitivity analyses were conducted to test model robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>For patients with PD-L1 CPS \u2a7e1, the PTC regimen provided an additional 0.33 QALY at an incremental cost of $247,474.27 compared to TC, resulting in an ICER of $750,750.50 per QALY\u2014well above the U.S. willingness-to-pay threshold of $150,000\/QALY. In CPS\u2009&lt;\u20091 and overall populations, ICERs were \u2212$377,258.54 and $957,550.19 per QALY, respectively. In sequential treatment analyses, the TC-based sequences were more cost-effective than PTC-based sequences, with the ICERs of PTC-based regimens exceeding $745063.32 per QALY. Sensitivity analyses confirmed the robustness of these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>From a U.S. payer perspective, PTC is not cost-effective for HER2-positive metastatic G\/GEJ adenocarcinoma at current prices, regardless of PD-L1 CPS status or treatment sequence. Price reduction strategies and biomarker-driven therapy selection are warranted to improve economic value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251378294","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T11:01:41Z","timestamp":1759057301000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5252-5647","authenticated-orcid":false,"given":"Caicong","family":"You","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"The School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8456-3756","authenticated-orcid":false,"given":"Jiahao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0178-9853","authenticated-orcid":false,"given":"Jianying","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"The School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"The School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"The School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-4882","authenticated-orcid":false,"given":"Hongfu","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China"},{"name":"The School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8382-7868","authenticated-orcid":false,"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, China"},{"name":"The School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou 350001, China"},{"name":"The School of Pharmacy, Fujian Medical University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,28]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Stomach (Gastric) Cancer key statistics 2023. https:\/\/www.cancer.org\/cancer\/types\/stomach-cancer\/about\/key-statistics.html (accessed 14 October 2024)."},{"key":"e_1_3_4_3_2","unstructured":"Cancer of the Stomach\u2014Cancer stat facts. SEER 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/stomach.html (accessed 14 October 2024)."},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-014-0402-y"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_3_4_6_2","unstructured":"Research C for DE and. FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas. FDA 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas (accessed 21 October 2024)."},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30169-8"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04161-3"},{"key":"e_1_3_4_9_2","unstructured":"Center for Drug Evaluation and Research. FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer. FDA 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer (accessed 13 October 2024)."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.03.1608"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004413"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6389"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503119"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2024.2341859"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2408121"},{"key":"e_1_3_4_16_2","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller RD.","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med 1987; 317: 1098.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_17_2","first-page":"1","article-title":"Anthropometric reference data for children and adults: United States, 2015\u20132018","volume":"3","author":"Fryar CD","year":"2021","unstructured":"Fryar CD, Carroll MD, Gu Q, et al. Anthropometric reference data for children and adults: United States, 2015\u20132018. Vital Health Stat 3 2021; 1\u201344.","journal-title":"Vital Health Stat"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1066380"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.390"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.12.012"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e6"},{"key":"e_1_3_4_22_2","first-page":"113","article-title":"Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma","volume":"28","author":"Li S","year":"2020","unstructured":"Li S, Liu J, Bowers C, et al. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma. Support Care Cancer 2020; 28: 113\u2013122.","journal-title":"Support Care Cancer"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006052"},{"key":"e_1_3_4_24_2","unstructured":"Health and Quality of Life Outcomes. Health state utilities for non small cell lung cancer 2008. https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/1477-7525-6-84 (accessed 9 July 2025)."},{"key":"e_1_3_4_25_2","unstructured":"CMS. ASP pricing files 2024. https:\/\/www.cms.gov\/medicare\/payment\/part-b-drugs\/asp-pricing-files (accessed 9 October 2024)."},{"key":"e_1_3_4_26_2","unstructured":"CMS Search the physician fee schedule 2024. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search?Y=0&T=4&HT=0&CT=3&H1=G0307&M=5 (accessed 9 October 2024)."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34502"},{"key":"e_1_3_4_28_2","article-title":"Economic cost\u2013utility analysis of stage-directed gastric cancer treatment","volume":"5","author":"Powell AG","year":"2022","unstructured":"Powell AG, Wheat JR, Eley C, et al. Economic cost\u2013utility analysis of stage-directed gastric cancer treatment. BJS Open 2022; 5: zrab129.","journal-title":"BJS Open"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/1049909119836204"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-022-01567-z"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9"},{"key":"e_1_3_4_34_2","unstructured":"Tom R. Halfhill Tom\u2019s inflation calculator. https:\/\/www.halfhill.com\/inflation_js.html (2024 accessed 21 July 2024)."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.12477"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(15)00069-8"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458348"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-023-00391-5"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251378294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251378294","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251378294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:21Z","timestamp":1777588401000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251378294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":37,"alternative-id":["10.1177\/17588359251378294"],"URL":"https:\/\/doi.org\/10.1177\/17588359251378294","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"17588359251378294"}}